Dipna Pharmachem Limited has issued a clarification to BSE Limited regarding significant movement in its share price, stating that no material information from the company caused the volatility.

Company Response to BSE Inquiry

In a letter dated April 7, 2026, Dipna Pharmachem Limited responded to BSE's inquiry about significant price movement in the company's scrip. The company clarified that it has no price-sensitive or material information that could result in or has resulted in significant movement in its share price.

Regulatory Compliance Status

The pharmaceutical company confirmed that it has made all necessary disclosures under the applicable regulations of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. These disclosures were made within the stipulated time period as per regulations and may have a possible impact or cause fluctuation on the company's share price.

Market Movement Attribution

Dipna Pharmachem Limited emphasized that there is currently no event, information, or announcement that needs to be reported to the stock exchange. The company attributed the volatility in its share price to natural market forces rather than any company-specific developments.

The response was signed by Keyur Dipakkumar Shah, Managing Director (DIN: 03167258), and submitted to BSE Limited's Phiroze Jeejeebhoy Tower office in Mumbai. The company requested BSE to take the clarification on record.

Dipna Pharmachem Limited has successfully obtained trading approval from BSE Limited for 22,44,000 fully paid-up equity shares issued through warrant conversion on a preferential basis. The approval, which became effective from January 20, 2026, marks the completion of a comprehensive application process initiated by the pharmaceutical company earlier in 2025.

Share Allotment Details

The equity shares carry specific parameters that define their structure and pricing:

The total value of the preferential allotment amounts to approximately ₹29.27 crores, calculated based on the issue price of ₹13.05 per share. These shares were issued pursuant to the conversion of warrants that were originally approved for issuance on a preferential basis.

Application Timeline and Process

The company followed a structured approach to obtain the necessary approvals:

• March 13, 2025: Submission of in-principle application to BSE for convertible warrants issuance
• December 9, 2025: Filing of listing application for equity shares pursuant to warrant conversion
• January 19, 2026: BSE issued approval letter and notice to trading members
• January 20, 2026: Trading approval became effective

The systematic progression through regulatory requirements demonstrates the company's compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, under Regulation 30.

Regulatory Compliance and Documentation

Dipna Pharmachem Limited, incorporated under CIN L24100GJ2011PLC066400, maintained transparency throughout the process by providing timely intimations to the stock exchange. The company's registered office is located at A/211, Siddhi Vinayak Complex, Near D.A.V. School, Makarba, Ahmedabad – 380055.

The approval was communicated through BSE's Notice No. 20260119-16 dated January 19, 2026, which was made available to all trading members of the exchange. This notice serves as the official communication regarding the listing and trading commencement of the newly issued equity shares.

Corporate Authorization

The regulatory filings were authorized by Keyur Dipakkumar Shah, Managing Director (DIN: 03167258), who digitally signed the intimation letter to BSE on January 21, 2026. The digital signature authentication confirms the authenticity and legal validity of the corporate communication submitted to the stock exchange.

This successful completion of the warrant conversion and subsequent trading approval enhances the company's equity base while providing liquidity options for the allottees in the secondary market.